S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Total Current Assets
ÂĄ10.7B
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
5%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Assets
ÂĄ28.9B
CAGR 3-Years
19%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Assets
ÂĄ15.1B
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Assets
ÂĄ34.8B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Assets
ÂĄ36.4B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
12%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Assets
ÂĄ775.8m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.99 CNY
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Total Current Assets?
Total Current Assets
10.7B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Total Current Assets amounts to 10.7B CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
5%

Over the last year, the Total Current Assets growth was -10%.

Back to Top